mutations presented the fact that, as discussed underneath, CLL therapy is based to the presence or absence of those mutations. The current consensus is the fact, aside from clonal mutations, subclonal mutations that has a variant allelic frequency ranging from 5 to ten% (and as a consequence beneath the brink of detection by common molecular strat